ECCT as sole Alternative Treatment for Testicular Cancer Metastasis to Lungs and Lymph Nodes

First Session of ECCT

Mr Khairul, 39-year-old male in Malaysia, had been dealing with a right testicular swelling for the past six years, which gradually increased in size. In November 2023, his condition worsened, and he sought medical attention at the Hospital. Imaging confirmed the diagnosis of right testicular carcinoma with metastasis to the lungs and lymph nodes, including large para-aortic nodes.

After careful consideration, he agreed to undergo chemotherapy (BEP regimen) after completing four cycles, his tumor size was reduced by a bit, and his overall condition stabilized, despite metastasis to the lungs and spine. Although he experience side effects such as fatigue and a reduced appetite, but there was no pain or bleeding. However, subsequent chemotherapy does not show further effect and his tumour continue to grow and tumour marker continue to rise. His oncology then stopped chemotherapy hereafter.

First Free Trial in JRX Global Centre

In Feb 2025 during Chinese New Year, he came across ECCT and decided to give it a try as the Alternative Treatment for Testicular Cancer. Prior to the initiation of ECCT, Khairul’s serum AFP levels were on an increasing trend, indicating active disease progression. His hemoglobin (HB) was also low, reflecting anemia likely due to tumor burden and previous chemotherapy effects.

Date	AFP
04/02/2025	11.3
09/03/2025	8.6
21/04/2025	7.0
19/06/2025	5.5
06/08/2025	4.7
13/10/2025	3.4
15/01/2026	3.2

Since beginning ECCT, now over eight and a half months, Khairul's condition has markedly improved. His body weight has stabilized and increased slightly from 52kg to 59kg, suggesting an improvement in general physical status. Even good news is, his recent blood tests show a significant decline in AFP levels from 11.3 to return normal at 7.0, continue to reduced to 5.5 and reaching 3.2 by now. Aside, based on ultrasound imaging, lesion size appears smaller compared to the CT scan performed in January 2025, indicating a favorable response to the treatment by reducing tumor size, activity and metastasis.

Furthermore, his hemoglobin levels and albumin globulin ratio have risen, reflecting improved blood health, reduced anemia and improved liver function. Notably, he reports no new symptoms of pain or discomfort, along his treatment with ECCT.

A year and a half after consistent use of ECCT, his latest scan has shown several encouraging

improvements despite no surgery:

Finding	Initial CT (Jan/Feb 2025)	CT 14 July 2026	Change
Primary right testicular tumour	13.8 × 15 × 25.2 cm	10.4 × 11.3 × 13.3 cm	Marked reduction in size (~70% reduction in tumour volume)
Lung metastases	Two suspicious metastatic nodules (RUL 1.3 × 1.0 cm and RLL 0.9 × 0.7 cm)	No suspicious lung metastases. Only a 3 mm calcified left lower lobe nodule, likely granuloma	Resolution of previous metastatic lung nodules
Paraaortic lymph nodes	Large matted para-aortic/aortocaval nodes measuring 4.0 × 8.1 cm, encasing abdominal vessels	No enlarged abdominal or pelvic lymph nodes reported	Significant regression of lymph node disease.

This case exemplifies how ECCT can effectively contribute to controlling advanced metastatic testicular cancer, improving biochemical markers, and enhancing the patient’s quality of life. Khairul’s progress continues to be closely monitored, with ongoing assessments to optimize his treatment plan.